Celadon Pharmaceuticals (LON:CEL) Sets New 12-Month Low – Time to Sell?

Celadon Pharmaceuticals Plc (LON:CELGet Free Report)’s stock price hit a new 52-week low during trading on Monday . The company traded as low as GBX 12 ($0.15) and last traded at GBX 13 ($0.16), with a volume of 24529 shares. The stock had previously closed at GBX 12.86 ($0.16).

Celadon Pharmaceuticals Stock Performance

The business has a fifty day simple moving average of GBX 27.40 and a two-hundred day simple moving average of GBX 51.19. The company has a market cap of £8.74 million, a PE ratio of -158.75 and a beta of -0.26. The company has a debt-to-equity ratio of 194.82, a current ratio of 1.92 and a quick ratio of 6.97.

About Celadon Pharmaceuticals

(Get Free Report)

Celadon Pharmaceuticals Plc engages in the research, cultivation, manufacturing, and sale of cannabis-based medicines. The company primarily focuses on growing indoor hydroponic cannabis for use in medicinal products used to treat chronic pain, as well as autism spectrum disorders. Celadon Pharmaceuticals Plc was founded in 2018 and is headquartered in London, the United Kingdom.

Further Reading

Receive News & Ratings for Celadon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celadon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.